Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17193469 | 0.70 | — | — | |
| SCHEMBL15746205 | 0.67 | ALDH1A1 (0.33) | — | |
| SCHEMBL15746235 | 0.67 | ALDH1A1 (0.33) | TDP1 | |
| SCHEMBL15746201 | 0.63 | — | — | |
| SCHEMBL15746236 | 0.61 | — | — | |
| SCHEMBL17014257 | 0.61 | — | — | |
| SCHEMBL17014263 | 0.60 | — | — | |
| SCHEMBL712833 | 0.57 | CES1 (0.69) | — | |
| SCHEMBL22928678 | 0.57 | CES1 (0.55) | TDP1 | |
| SCHEMBL8737611 | 0.57 | KDM4E (0.41) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9416139-B2 | Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-08-16 | — | — | US | disclosed |
| US-9303061-B2 | Spiro compounds as Hepatitis C virus inhibitors | Sunshine Luke Pharma Co., Ltd. (CN) | 2016-04-05 | — | — | US | disclosed |
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299215-A1 | SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF | HAVCR2, SLC10A1, SORD | TDP1 4117/4885PDE7A 3319/4885 |
| US-20140147412-A1 | SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | HAVCR2, SORD, SLC10A1 | TDP1 3253/4885PDE7A 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.